sur MEDESIS S.A. (isin : FR0010844464)
MEDESIS PHARMA: Judicial liquidation procedure opened
MEDESIS PHARMA, a pharmaceutical biotechnology company, has announced the opening of liquidation proceedings. This decision was made by the Montpellier Commercial Court on March 7, 2025. The company had initially initiated safeguard proceedings on September 29, 2023, which were converted into receivership on November 8, 2024. The lack of prospects for reorganizing the company led to this final act.
As a result, MEDESIS PHARMA's shares were suspended on March 10, 2025. The company's assets may not be sufficient to repay shareholders. Aonys® technology, while promising, has not prevented this fate. Investors are informed of the risks associated with the company's liabilities.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MEDESIS S.A.